Cellular Therapy
From the Journals
Novel approach brings hospice-bound MM patient into remission
With the use of next-generation genomic sequencing and a novel triple therapy, a patient who had relapsed after CAR T-cell therapy was brought...
Conference Coverage
Many die waiting for `last-chance’ therapy
Blood cancer patients, especially those with myeloma, face hospice and death while awaiting CAR T-cell therapy.
Feature
CAR T-cell therapy turns 10 and finally earns the word ‘cure’
“We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me.”
Conference Coverage
‘Superior’ CLL regimen cuts chemo in half
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...
News
FDA approves liso-cel as second-line therapy for LBCL
Liso-cel could now become a “new standard of care for patients after failure of first-line therapy,” offering significantly improved outcomes for...
Latest News
FDA approves new CAR T-cell treatment for multiple myeloma
Study results show that this treatment for refractory/relapsed multiple myeloma can provide deep, durable responses and long treatment-free...
Latest News
EMA gives green light to new CAR T-cell therapy
The committee also recommended approval of a biosimilar product for pegfilgrastim.
From the Journals
CLL patients ‘cured’: 10 years post infusion, CAR T cells persist
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
Conference Coverage
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
Conference Coverage
CAR-T in children branching out to solid tumors